High Tide Q3: Stock May Drop Further To Offer Better Entry Points

High Tide Inc. (NASDAQ:HITI) reported record Q3-2025 financial results, achieving CA$149.7 million in revenue, CA$40.1 million in gross profit, and CA$7.7 million in free cash flow, alongside a positive net income. This strong operational performance is further enhanced by its leading Canadian cannabis retail market share and strategic expansion into the German medical cannabis market through the acquisition of Remexian. While the company's stock has seen significant gains, partly due to broader sector speculation around U.S. cannabis rescheduling, the article notes that this wider market rally has since cooled, potentially introducing volatility despite High Tide's robust fundamentals and continued growth prospects.

Analysis

High Tide Inc. has reported a record-setting Q3-2025, demonstrating significant operational strength with all-time high revenues of CA$149.7 million (a 14% YoY increase), gross profit of CA$40.1 million, and free cash flow of CA$7.7 million. This performance is underpinned by a robust Canadian retail operation, which holds a 12% market share and saw same-store sales grow 7.4% YoY, bolstered by a successful membership program that grew its core user base by 39%. A key strategic development is the company's entry into the German medical cannabis market via the acquisition of Remexian, a major importer responsible for 16% of the market's volume and reporting CA$120 million in revenue for the six months ending March 2025. Despite these fundamental strengths, which include a return to positive net income (CA$0.8 million), some segments like e-commerce showed weaker performance. The company's stock price, up 69% over the last year, has benefited from a broader sector rally tied to U.S. cannabis rescheduling speculation, which has since subsided. The article flags a potential valuation concern, with the stock trading at nearly 3x its book value, suggesting a disconnect between the company's solid execution and a market price influenced by volatile external sentiment.

Key Decisions for Investors

• Investors should recognize the dichotomy between High Tide's strong fundamentals, including record cash flow and strategic German expansion, and the stock's price, which has been partly inflated by a now-fading, sector-wide rally on U.S. regulatory hopes.
• Given the article's note that the stock may be overvalued at nearly 3x book value, it may be prudent to await a potential price correction driven by sector-wide cooling to find a more fundamentally-backed entry point.
• Monitor the financial contribution and integration of the newly acquired German firm, Remexian, as the next major growth catalyst, while also tracking U.S. cannabis rescheduling news, which remains a key source of market volatility for the sector.
• While the company's financial health appears solid with assets outweighing liabilities, note that its cash position was recently bolstered by a CA$25.2 million loan, bringing total debt to CA$69 million, a factor to consider when assessing its balance sheet.